Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study.

NCT04571437 is registered in ClinicalTrials.gov with Cairo University as lead sponsor.

NCT NCT04571437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study.
Lead sponsor
Cairo University
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2020
Completion date
April 30, 2022
Enrollment
204 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, estrogen receptor-positive breast cancer, metastatic breast cancer